{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE307nnn/GSE307905/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307905"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Tandem bispecific IL-7 receptor agonist antibody","description":"Interleukin-7 (IL-7) is essential for T cell immunity, but the therapeutic application of existing IL-7 therapies is limited by narrow therapeutic window and suboptimal pharmacokinetics. To address this, we engineered a fully human tandem bispecific antibody, TB4, that functions as a potent IL-7 receptor (IL-7R) agonist by cross-linking the IL-7Rα and γc subunits. In primary human T cells, TB4 exhibited potent bispecific binding and induced sustained STAT5 signaling, a feature potentially associated with its slow antibody internalization rate. TB4 promoted T cell survival and the preferential expansion of CD4⁺ memory T cells. Notably, transcriptomic analysis revealed that TB4 induces a unique transcriptional signature enriched in genes associated with antiviral and innate immune responses, distinguishing it from native IL-7. These findings highlight TB4 as a promising IL-7R agonist with the potential to act as a subset-specific T cell immunomodulator, shaping both the expansion and functional profile of T cells.","dates":{"publication":"2026/06/29"},"accession":"GSE307905","cross_references":{"GSM":["GSM9233780","GSM9233782","GSM9233781","GSM9233777","GSM9233776","GSM9233787","GSM9233779","GSM9233778","GSM9233784","GSM9233783","GSM9233786","GSM9233785"],"GPL":["21697"],"GSE":["307905"],"taxon":["Homo sapiens"]}}